[go: up one dir, main page]

TR201004464A2 - Kemik erimesi için formülasyon. - Google Patents

Kemik erimesi için formülasyon.

Info

Publication number
TR201004464A2
TR201004464A2 TR2010/04464A TR201004464A TR201004464A2 TR 201004464 A2 TR201004464 A2 TR 201004464A2 TR 2010/04464 A TR2010/04464 A TR 2010/04464A TR 201004464 A TR201004464 A TR 201004464A TR 201004464 A2 TR201004464 A2 TR 201004464A2
Authority
TR
Turkey
Prior art keywords
bone resorption
formulation
genistein
vitamin
prevention
Prior art date
Application number
TR2010/04464A
Other languages
English (en)
Inventor
B�Lg�� Mahmut
Original Assignee
B�Lg�� Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by B�Lg�� Mahmut filed Critical B�Lg�� Mahmut
Priority to TR2010/04464A priority Critical patent/TR201004464A2/tr
Priority to PCT/TR2011/000150 priority patent/WO2012002918A1/en
Priority to EP11764885.7A priority patent/EP2575758A1/en
Publication of TR201004464A2 publication Critical patent/TR201004464A2/tr
Priority to US13/692,163 priority patent/US20130164342A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Mevcut buluş kemik erimesi ve kemik erimesi ile ilişkili hastalıkların önlenmesinde ve tedavisinde kullanılmak üzere kalsiyum, genistein ve D vitamini içeren biyoyararlanımı yüksek farmasötik bileşimlere ilişkindir.
TR2010/04464A 2010-06-03 2010-06-03 Kemik erimesi için formülasyon. TR201004464A2 (tr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
TR2010/04464A TR201004464A2 (tr) 2010-06-03 2010-06-03 Kemik erimesi için formülasyon.
PCT/TR2011/000150 WO2012002918A1 (en) 2010-06-03 2011-06-02 Formulation for osteoporosis
EP11764885.7A EP2575758A1 (en) 2010-06-03 2011-06-02 Formulation for osteoporosis
US13/692,163 US20130164342A1 (en) 2010-06-03 2012-12-03 Formulations for osteoporosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2010/04464A TR201004464A2 (tr) 2010-06-03 2010-06-03 Kemik erimesi için formülasyon.

Publications (1)

Publication Number Publication Date
TR201004464A2 true TR201004464A2 (tr) 2012-11-21

Family

ID=44759752

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2010/04464A TR201004464A2 (tr) 2010-06-03 2010-06-03 Kemik erimesi için formülasyon.

Country Status (3)

Country Link
EP (1) EP2575758A1 (tr)
TR (1) TR201004464A2 (tr)
WO (1) WO2012002918A1 (tr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013043142A1 (en) * 2011-08-08 2013-03-28 Mahmut Bilgic Production method for pharmaceutical formulations comprising an isoflavone
WO2013089654A1 (en) * 2011-12-16 2013-06-20 Mahmut Bilgic Effervescent formulations comprising genistein
EP2919744B1 (en) * 2012-11-16 2020-09-02 EUSA Pharma (UK) Ltd Effervescent tablet
CN105616441B (zh) * 2014-11-05 2018-08-14 澳美制药厂有限公司 碳酸钙维生素d3片及其制备方法
RU2582973C1 (ru) * 2015-03-10 2016-04-27 федеральное государственное бюджетное учреждение "Северо-Западный федеральный медицинский исследовательский центр" Министерства здравоохранения Российской Федерации (ФГБУ "СЗФМИЦ" Минздрава России) Антиостеопорозное средство
US10881634B2 (en) * 2017-12-07 2021-01-05 Hughes Biotechnology Co., Ltd Method for treatment or prevention of a disease associated with a decrease in bone mass and method of improving bone architecture and bio mechanical strength of bone
CN109172531A (zh) * 2018-09-04 2019-01-11 安士制药（中山）有限公司 一种复合碳酸钙/维生素d3片剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1370257B1 (en) * 2001-03-15 2007-07-25 DSM IP Assets B.V. COMPOSITION FOR THE PREVENTION OF OSTEOPOROSIS consisting of A COMBINATION OF ISOFLAVONES AND POLYUNSATURATED FATTY ACIDS
ITFI20030194A1 (it) * 2003-07-17 2005-01-18 Menarini Int Operations Lu Sa Composizione farmaceutiche effervescenti contenenti
CN1589786A (zh) * 2003-09-01 2005-03-09 郑州博凯医药保健品有限公司 一种含大豆异黄酮的复合泡腾制剂
JPWO2005046702A1 (ja) * 2003-09-19 2007-05-24 サンスター株式会社 歯槽骨の吸収及び歯根膜喪失を抑制する方法及びそれに用いる内服組成物
US20070207225A1 (en) * 2006-03-03 2007-09-06 Francesco Squadrito Genistein modulated reduction of cardiovascular risk factors

Also Published As

Publication number Publication date
EP2575758A1 (en) 2013-04-10
WO2012002918A1 (en) 2012-01-05

Similar Documents

Publication Publication Date Title
UA109010C2 (en) Morpholino pyrividines and their use in therapy
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
CL2012003293A1 (es) Compuestos derivados de aminopirimidina, como moduladores de la proteina quinasa rica en repeticiones leucina 2 (lrrk2); composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de parkinson.
EA201390060A1 (ru) Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
UA110612C2 (uk) Похідні 1-аміно-2-циклопропілетилборонової кислоти
EA201200551A1 (ru) Фармацевтическая композиция, фармацевтическая дозированная форма, способы их получения и применения для лечения
IN2012DN00971A (tr)
EP4414376A3 (en) Novel depsipeptide and uses thereof
MX348823B (es) Formulaciones estables de linaclotida.
EA201270741A1 (ru) Пероральные композиции и липофильные соли метилналтрексона
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
MX347105B (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona.
TR201004464A2 (tr) Kemik erimesi için formülasyon.
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
EA201590364A1 (ru) Применение орвепитанта, его солей и кристаллических форм и композиций, его содержащих, для лечения зуда
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
EA201171414A1 (ru) Ингибиторы белков семейства iap
CY1116158T1 (el) Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.
MX2013002295A (es) 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
CY1118255T1 (el) Υποκατεστημενα 6-αμινο-νικοτιναμιδια τα οποια φερουν μια ομαδα που περιεχει οη ως διαμορφωτες των kcnq2/3
TR201100151A2 (tr) İbandronate formülasyonu.
BR112015023872A2 (pt) composição compreendendo arabinogalactano e poliofenóis de árvores de lariço
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.
EA201500366A1 (ru) Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора